Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia

Matt E. Kalaycio, Manisha Kukreja, Ann E. Woolfrey, Jeffrey Szer, Jorge Cortes, Richard T. Maziarz, Brian J. Bolwell, Andreas Buser, Edward Copelan, Robert Peter Gale, Vikas Gupta, Dipnarine Maharaj, David I. Marks, Steven Z. Pavletic, Mary M. Horowitz, Mukta Arora

Research output: Contribution to journalArticle

Abstract

The poor prognosis of patients with prolymphocytic leukemia (PLL) has led some clinicians to recommend allogeneic hematopoietic cell transplant (HCT). However, the data to support this approach is limited to case-reports and small case series. We reviewed the database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to determine outcomes after allotransplant for patients with PLL. We identified 47 patients with a median age of 54 years (range: 30-75 years). With a median follow-up of 13 months, progression-free survival (PFS) was 33% (95% confidence interval [CI] 20%-47%) at 1 year. The most common cause of death was relapse or progression in 49%. The cumulative incidence of treatment-related mortality (TRM) at 1-year posttransplant was 28%. The small patient population prohibited prognostic factor analysis, but these data support consideration of allotransplant for PLL. Further study of a larger population of patients is needed to determine which patients are more likely to benefit.

Original languageEnglish (US)
Pages (from-to)543-547
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Volume16
Issue number4
DOIs
StatePublished - Apr 1 2010
Externally publishedYes

Fingerprint

Prolymphocytic Leukemia
Transplants
Population
Statistical Factor Analysis
Disease-Free Survival
Cause of Death
Bone Marrow
Databases
Confidence Intervals
Recurrence
Mortality
Incidence
Research

Keywords

  • Allogeneic stem cell transplantation
  • Prolymphocytic leukemia

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Kalaycio, M. E., Kukreja, M., Woolfrey, A. E., Szer, J., Cortes, J., Maziarz, R. T., ... Arora, M. (2010). Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia. Biology of Blood and Marrow Transplantation, 16(4), 543-547. https://doi.org/10.1016/j.bbmt.2009.11.021

Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia. / Kalaycio, Matt E.; Kukreja, Manisha; Woolfrey, Ann E.; Szer, Jeffrey; Cortes, Jorge; Maziarz, Richard T.; Bolwell, Brian J.; Buser, Andreas; Copelan, Edward; Gale, Robert Peter; Gupta, Vikas; Maharaj, Dipnarine; Marks, David I.; Pavletic, Steven Z.; Horowitz, Mary M.; Arora, Mukta.

In: Biology of Blood and Marrow Transplantation, Vol. 16, No. 4, 01.04.2010, p. 543-547.

Research output: Contribution to journalArticle

Kalaycio, ME, Kukreja, M, Woolfrey, AE, Szer, J, Cortes, J, Maziarz, RT, Bolwell, BJ, Buser, A, Copelan, E, Gale, RP, Gupta, V, Maharaj, D, Marks, DI, Pavletic, SZ, Horowitz, MM & Arora, M 2010, 'Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia', Biology of Blood and Marrow Transplantation, vol. 16, no. 4, pp. 543-547. https://doi.org/10.1016/j.bbmt.2009.11.021
Kalaycio, Matt E. ; Kukreja, Manisha ; Woolfrey, Ann E. ; Szer, Jeffrey ; Cortes, Jorge ; Maziarz, Richard T. ; Bolwell, Brian J. ; Buser, Andreas ; Copelan, Edward ; Gale, Robert Peter ; Gupta, Vikas ; Maharaj, Dipnarine ; Marks, David I. ; Pavletic, Steven Z. ; Horowitz, Mary M. ; Arora, Mukta. / Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia. In: Biology of Blood and Marrow Transplantation. 2010 ; Vol. 16, No. 4. pp. 543-547.
@article{74aaaab59216495eb373d4bfff1331fe,
title = "Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia",
abstract = "The poor prognosis of patients with prolymphocytic leukemia (PLL) has led some clinicians to recommend allogeneic hematopoietic cell transplant (HCT). However, the data to support this approach is limited to case-reports and small case series. We reviewed the database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to determine outcomes after allotransplant for patients with PLL. We identified 47 patients with a median age of 54 years (range: 30-75 years). With a median follow-up of 13 months, progression-free survival (PFS) was 33{\%} (95{\%} confidence interval [CI] 20{\%}-47{\%}) at 1 year. The most common cause of death was relapse or progression in 49{\%}. The cumulative incidence of treatment-related mortality (TRM) at 1-year posttransplant was 28{\%}. The small patient population prohibited prognostic factor analysis, but these data support consideration of allotransplant for PLL. Further study of a larger population of patients is needed to determine which patients are more likely to benefit.",
keywords = "Allogeneic stem cell transplantation, Prolymphocytic leukemia",
author = "Kalaycio, {Matt E.} and Manisha Kukreja and Woolfrey, {Ann E.} and Jeffrey Szer and Jorge Cortes and Maziarz, {Richard T.} and Bolwell, {Brian J.} and Andreas Buser and Edward Copelan and Gale, {Robert Peter} and Vikas Gupta and Dipnarine Maharaj and Marks, {David I.} and Pavletic, {Steven Z.} and Horowitz, {Mary M.} and Mukta Arora",
year = "2010",
month = "4",
day = "1",
doi = "10.1016/j.bbmt.2009.11.021",
language = "English (US)",
volume = "16",
pages = "543--547",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia

AU - Kalaycio, Matt E.

AU - Kukreja, Manisha

AU - Woolfrey, Ann E.

AU - Szer, Jeffrey

AU - Cortes, Jorge

AU - Maziarz, Richard T.

AU - Bolwell, Brian J.

AU - Buser, Andreas

AU - Copelan, Edward

AU - Gale, Robert Peter

AU - Gupta, Vikas

AU - Maharaj, Dipnarine

AU - Marks, David I.

AU - Pavletic, Steven Z.

AU - Horowitz, Mary M.

AU - Arora, Mukta

PY - 2010/4/1

Y1 - 2010/4/1

N2 - The poor prognosis of patients with prolymphocytic leukemia (PLL) has led some clinicians to recommend allogeneic hematopoietic cell transplant (HCT). However, the data to support this approach is limited to case-reports and small case series. We reviewed the database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to determine outcomes after allotransplant for patients with PLL. We identified 47 patients with a median age of 54 years (range: 30-75 years). With a median follow-up of 13 months, progression-free survival (PFS) was 33% (95% confidence interval [CI] 20%-47%) at 1 year. The most common cause of death was relapse or progression in 49%. The cumulative incidence of treatment-related mortality (TRM) at 1-year posttransplant was 28%. The small patient population prohibited prognostic factor analysis, but these data support consideration of allotransplant for PLL. Further study of a larger population of patients is needed to determine which patients are more likely to benefit.

AB - The poor prognosis of patients with prolymphocytic leukemia (PLL) has led some clinicians to recommend allogeneic hematopoietic cell transplant (HCT). However, the data to support this approach is limited to case-reports and small case series. We reviewed the database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to determine outcomes after allotransplant for patients with PLL. We identified 47 patients with a median age of 54 years (range: 30-75 years). With a median follow-up of 13 months, progression-free survival (PFS) was 33% (95% confidence interval [CI] 20%-47%) at 1 year. The most common cause of death was relapse or progression in 49%. The cumulative incidence of treatment-related mortality (TRM) at 1-year posttransplant was 28%. The small patient population prohibited prognostic factor analysis, but these data support consideration of allotransplant for PLL. Further study of a larger population of patients is needed to determine which patients are more likely to benefit.

KW - Allogeneic stem cell transplantation

KW - Prolymphocytic leukemia

UR - http://www.scopus.com/inward/record.url?scp=77949271439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949271439&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2009.11.021

DO - 10.1016/j.bbmt.2009.11.021

M3 - Article

C2 - 19961946

AN - SCOPUS:77949271439

VL - 16

SP - 543

EP - 547

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 4

ER -